Bar, I can only point to Fate Therpeutics and other partnerships in bio-tech. J&J partnered with them because they are the clear market leader in iSPC cells in cancer:
https://seekingalpha.com/news/3707430-fate-therapeutics-is-expected-to-dominate-in-cell-therapy-despite-gileads-entry. To keep this thread relevant to the title, FATE recently got IND approval with the FDA:
https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-fda-clearance-ind-application-firstGiven J&J's partnership with Fate, whilst you cannot get too excited, you cannot deny this raises the probability of J&J venturing forward with OCC given success there:https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-fda-clearance-ind-application-firstThose partnerships are usually accompanied by an initial equity investment (the big Pharma partner gets to buy in at great levels on a small bio-tech that will inevitably rally on news of the partnership) and milestone payments. Those are huge revenue streams for a small company like OCC (if a partnership eventuates) whilst the company advances trials. We also have the revenue stream of emerging commercialisation from CelGro.
I am on PAR (small) and its stock price as drfited -24% YTD. OCC has clmibed 7%. Both are value for me, but I was on an American investment forum last night explaining OCC's treatments. They were pinching themselves that it was $100 million mkt cap.
It is complete estimation, but I would not be surprised if J&J partnered and granted anywhere between a $20-50 initial equity investment and $50-150 million in milestone payments, IF, they venture into a partnership.
There are some 1500 stem-cell trials round the world at the moment. Most in Mesenchymal cells. Most will fail to materalize into cash flow. OCC with its teoncyte (and chondrocyte) niche has so much more to offer a big Pharma like J&J than just another MSc company. I've gone through the main stem-cell company over the years and picked out the best propsects in various applications (hence I landed on FATE). OCC's ATI by merit should by rights be the gold standard cellular treatment for tendons. It will be a loss to humanity if it gest passed over, tenocytes clearly the best path.
(20min delay)